Insider Filing Worth Mentioning: Nola Masterson Insider Selling for 3,305 Shares of Repros Therapeutics Inc (NASDAQ:RPRX)

November 23, 2016 - By Clifton Ray

Insider Filing Worth Mentioning: Nola Masterson Insider Selling for 3,305 Shares of Repros Therapeutics Inc (NASDAQ:RPRX)

Nola Masterson Insider Sell

The Repros Therapeutics Inc’s director, Nola Masterson, an insider made a sale of – 3,305 Repros Therapeutics Inc’s shares, based on the avg market share price of $2.0 of a share. The sold shares today has a value of approx. $6,445 USD.

Repros Therapeutics Inc (NASDAQ:RPRX) Ratings Coverage

Out of 3 analysts covering Repros Therapeutics (NASDAQ:RPRX), 1 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 33% are positive. Repros Therapeutics has been the topic of 5 analyst reports since August 20, 2015 according to StockzIntelligence Inc. The stock of Repros Therapeutics Inc (NASDAQ:RPRX) has “Hold” rating given on Thursday, August 20 by Zacks. The firm earned “Neutral” rating on Friday, October 30 by Ladenburg Thalmann. The stock of Repros Therapeutics Inc (NASDAQ:RPRX) has “Underperform” rating given on Friday, October 30 by Bank of America. The rating was upgraded by Ladenburg Thalmann on Wednesday, November 16 to “Buy”. The stock has “Hold” rating given by Brean Capital on Friday, October 30.

Insitutional Activity: The institutional sentiment increased to 1.08 in 2016 Q2. Its up 0.80, from 0.28 in 2016Q1. The ratio increased, as 16 funds sold all Repros Therapeutics Inc shares owned while 13 reduced positions. 3 funds bought stakes while 5 increased positions. They now own 5.35 million shares or 31.60% less from 7.82 million shares in 2016Q1.

Goldman Sachs accumulated 0% or 15,618 shares. Walleye Trading accumulated 0% or 900 shares. Bancorp Of Montreal Can, a Ontario – Canada-based fund reported 1,000 shares. Moreover, Northern Trust has 0% invested in Repros Therapeutics Inc (NASDAQ:RPRX) for 60,305 shares. Creative Planning accumulated 5,000 shares or 0% of the stock. The Missouri-based Benjamin F Edwards Inc has invested 0% in Repros Therapeutics Inc (NASDAQ:RPRX). State Bank Of Ny Mellon Corp last reported 0% of its portfolio in the stock. Blackrock Investment Ltd Liability Com holds 0% of its portfolio in Repros Therapeutics Inc (NASDAQ:RPRX) for 4,324 shares. Geode Cap Management Ltd Liability Com holds 0% or 123,376 shares in its portfolio. California Public Employees Retirement System last reported 0% of its portfolio in the stock. State Street has 0% invested in the company for 13,851 shares. Riverpoint Cap Mngmt Lc holds 0% of its portfolio in Repros Therapeutics Inc (NASDAQ:RPRX) for 11,000 shares. General Investors holds 396,123 shares or 0.07% of its portfolio. The British Columbia – Canada-based Connor Clark And Lunn Inv Mngmt Ltd has invested 0% in Repros Therapeutics Inc (NASDAQ:RPRX). Jpmorgan Chase reported 27,750 shares or 0% of all its holdings.

The stock increased 1.08% or $0.02 on November 23, hitting $1.88. About 132,157 shares traded hands. Repros Therapeutics Inc (NASDAQ:RPRX) has declined 34.74% since April 21, 2016 and is downtrending. It has underperformed by 40.07% the S&P500.

Repros Therapeutics, Inc. is a biopharmaceutical firm focused on the development of new drugs to treat hormonal and reproductive system disorders. The company has a market cap of $46.31 million. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. It currently has negative earnings. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.

According to Zacks Investment Research, “Zonagen Inc. is a biopharmaceutical company engaged in the development of products for the human reproductive system, including sexual dysfunction, vaccine adjuvants, products for fertility and female health as well as urological applications, specifically prostate cancer. Zonagen’s products to treat sexual dysfunction all incorporate phentolamine mesylate, an alpha-adrenergic blocker, as the active agent. Zonagen’s lead product, VASOMAX(R), is a rapidly disintegrating oral formulation of phentolamine for the treatment of male erectile dysfunction.”

Analysts await Repros Therapeutics Inc (NASDAQ:RPRX) to report earnings on March, 13.

More news for Repros Therapeutics Inc (NASDAQ:RPRX) were recently published by: Fool.com, which released: “Why Repros Therapeutics, Inc. Shares Are Soaring” on April 02, 2015. Seekingalpha.com‘s article titled: “Is It All Over For Repros Therapeutics?” and published on November 23, 2015 is yet another important article.

RPRX Company Profile

Repros Therapeutics, Inc., incorporated on August 20, 1987, is a biopharmaceutical firm focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Through its clinical program, the Company is focused on conducting a Phase IIb study for low dose oral Proellex in the treatment of uterine fibroids; conducting a Phase IIb vaginal administration study for Proellex in the treatment of uterine fibroids; conducting a Phase II study for low dose oral Proellex for the treatment of endometriosis, and conducting a Phase II proof of concept study for enclomiphene for the treatment of secondary hypogonadism.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>